Literature DB >> 3097150

Antigen-presenting T cells. II. Clonal responses of alloreactive and virus-specific self-restricted human cytotoxic T cell responses stimulated by T lymphoblasts.

D Kabelitz, K H Enssle, B Fleischer, J Reimann.   

Abstract

The capacity of various stimulator cell types to present alloantigens or viral antigens to resting human CD8+ cytotoxic lymphocyte precursors (CLP) was analyzed in a limiting dilution culture system. Cell sorter-separated T lymphoblasts of both CD4+ and CD8+ phenotypes but not resting T cells were found to efficiently stimulate the clonal development of allogeneic CD8+ CLP. Thus, 5000 CD4+ T lymphoblasts activated as many (one out of 200 to one out of 300) allogeneic CLP as 50,000 peripheral blood mononuclear stimulator cells. This potent stimulator activity was found in CD4+ and CD8+ T lymphoblasts activated by mitogen, anti-T3 monoclonal antibody, or mixed leukocyte reactions. Cytotoxic T cells generated in this system were highly specific for HLA class I antigens. Furthermore, T lymphoblasts infected with mumps virus efficiently induced development of autologous CLP into CTL clones that were virus specific and self-HLA restricted, as shown by split-well analysis. The possible in vivo significance of antigen-presenting T lymphoblasts is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3097150

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  T cell blast stimulation of MLR: role of interleukin 1 and interleukin 2.

Authors:  S Aaron
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

2.  Dendritic cells, the major antigen-presenting cells of the human colonic lamina propria.

Authors:  P Pavli; D A Hume; E Van De Pol; W F Doe
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

3.  Limiting-dilution analysis of human CTL differentiation. Requirement for a lymphokine-mediated differentiation signal.

Authors:  D W Horohov; N I Stocks; J P Siegel
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.